HC Surgical Specialists (HCSS) has reported lower earnings of $3.38 million for the 1HFY2025 ended Nov 30, 2024, a 2.1% decrease from $3.45 million in the same period a year ago.
This is mainly due to non-operational items, including a fair value loss on derivative financial instruments of approximately $0.43 million, and a loss arising from deemed disposal in an associate of $0.20 million.
This was offset by fair value gain on financial assets at fair value through profit or loss of $0.13 million. In the same period a year ago, this figure stood at $0.83 million.
The group’s gross profit grew by 5.1% in the 1HFY2025 to $8.40 million from $7.99 million in the same period a year ago.
Earnings per share for the period tracked 3.9% lower at 2.20 cents, from 2.29 cents in the same period a year ago.
Meanwhile, revenue for the group grew 3.4% to $9.94 million from $9.62 million.
See also: Qian Hu reverses from year earlier loss
The group is declaring an interim dividend of 0.80 cents per ordinary share, payable on March 13, 2025.
The group’s endoscopy and general practitioner centres, located jointly in Camden Centre, underwent renovation in October 2024 and are now back in operations.
CEO of HCSS, Dr. Heah Sieu Min said: “Completion of the renovation of the Camden Centre in December 2024 maximises the existing endoscopy centre space whilst revamping and retaining the GP clinic, to modernise and align both centres within one premise to streamline healthcare service, in order to continually provide quality primary and specialist healthcare to all Singapore residents.”
See also: GKE chalks up record interim earnings of $4.4 million, up 132.5% y-o-y
HCSS holds a direct interest in Medinex , Singapore Paincare Holdings and Aoxin, shareholdings of 22.66%, 2.44% and 0.34%, respectively.
Units in HC Surgical Specialists closed flat at 29 cents on Jan 14.
